|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Forma Therapeutics Holdings, Inc., (FMTX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
45,311,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Co.'s pipeline consists of four product candidates, two of which it is pursuing for its development, etavopivat for the treatment of sickle cell disease (SCD), and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Co.'s main product candidate, etavopivat, is an oral, once-daily, potentially disease-modifying therapy initially being studied for the treatment of SCD.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kelly Patrick F. |
SVP, Chief Medical Officer |
• – – |
2022-02-23 |
4 |
S |
$9.78 |
$51,283 |
D/D |
(5,245) |
64,884 |
|
- |
|
| Cook David N |
SVP, Chief Scientific Officer |
• – – |
2022-02-23 |
4 |
S |
$9.78 |
$34,524 |
D/D |
(3,531) |
16,469 |
|
- |
|
| Shegog Todd |
SVP, Chief Financial Officer |
• – – |
2022-02-23 |
4 |
S |
$9.78 |
$55,605 |
D/D |
(5,687) |
22,813 |
|
- |
|
| Wadlinger Mary E. |
See Remarks |
• – – |
2022-02-23 |
4 |
S |
$9.78 |
$45,798 |
D/D |
(4,684) |
134,521 |
|
- |
|
| Molina Arturo Md |
Director |
– • – |
2022-01-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,500 |
5,500 |
|
- |
|
| Lesser Brian Andrew |
SVP, CommercialOfficer |
• – – |
2021-11-15 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
- |
|
| Lesser Brian Andrew |
SVP, Commercial OfficerOfficer |
• – – |
2021-11-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,430 |
|
- |
|
| Wiggans Thomas G |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
| Frederick Wayne A.i. |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
| Vickers Selwyn M Md |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
| Clackson Timothy P |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
26,340 |
|
- |
|
| Kolchinsky Peter |
Director |
– • • |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
2,750 |
|
- |
|
| Fanucci Marsha |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
55,282 |
|
- |
|
| Wirth Peter |
Director |
– • – |
2021-06-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
130,415 |
|
- |
|
| Bishop John E |
Chief Technology Officer |
• – – |
2021-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
22,000 |
22,000 |
|
- |
|
| Shegog Todd |
SVP, Chief Financial Officer |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
28,500 |
28,500 |
|
- |
|
| Wadlinger Mary E. |
See Remarks |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
23,630 |
139,205 |
|
- |
|
| Kelly Patrick F. |
Chief Medical Officer |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
27,170 |
27,170 |
|
- |
|
| Potts Jeannette |
See Remarks |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
23,630 |
27,030 |
|
- |
|
| Lee Frank D. |
President and CEO |
• • – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
97,750 |
97,750 |
|
- |
|
| Cook David N |
SVP, Chief Scientific Officer |
• – – |
2021-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
| Potts Jeannette |
See Remarks |
• – – |
2020-12-30 |
4 |
OE |
$5.05 |
$17,170 |
D/D |
3,400 |
3,400 |
|
- |
|
| Hall Steven Edward |
Director |
– • – |
2020-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
2,106,828 |
2,404,069 |
|
- |
|
| Wellington Biomedical Innovation Master Investors |
10% Owner |
– – • |
2020-06-23 |
4 |
B |
$20.00 |
$20,000,000 |
D/D |
1,000,000 |
2,252,913 |
2.45 |
- |
|
| Wellington Biomedical Innovation Master Investors |
10% Owner |
– – • |
2020-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
1,252,913 |
1,252,913 |
|
- |
|
89 Records found
|
|
Page 2 of 4 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
